diabetes

News Story

02/04/2010

Metformin XR (extended release formulation) -- a medication used to treat type 2 diabetes -- appears to cause a small but significant decrease in body mass index (BMI) in non-diabetic obese adolescents when combined with a lifestyle intervention program, according to a report in the February issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.More »

01/14/2010

An overwhelming majority of people (90%) who have periodontal (gum) disease are also at high risk for diabetes and should be screened for diabetes, a New York University nursing-dental research team has found. The researchers also determined that half of those at risk had seen a dentist in the previous year, concluded that dentists should consider offering diabetes screenings in their offices, and described practical approaches to conducting diabetes screenings in dental offices.

The study, led by Dr. Shiela Strauss, Associate Professor of Nursing and Co-Director of the Statistics and Data Management Core for NYU’s Colleges of Dentistry and Nursing, examined data from 2,923 adult participants in the 2003-2004 National Health and Nutrition Examination Survey who had not been diagnosed with diabetes. The survey, conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention, was designed to assess the health and nutritional status of adults and children in the United States.More »

01/09/2010

A new study has shown that metformin, a drug often used in the treatment of diabetes mellitus, is safe for use in treating patients who have both diabetes and advanced heart failure. The study was published in the Journal of Cardiac Failure by researchers at the David Geffen School of Medicine at UCLA.

"There may be over two million individuals with heart failure and type II diabetes mellitus in the U. S. alone, so this important finding will have fairly broad impact," said Dr. Tamara Horwich, senior author of the study and an assistant professor of medicine in the division of cardiology at the David Geffen School of Medicine at UCLA.More »

12/05/2009

Sulphonylureas, a type of drug widely used to treat type 2 diabetes, carries a greater risk of heart failure and death compared with metformin, another popular antidiabetes drug.

The findings, published on the British Medical Journal website, suggest clinically important differences in the cardiovascular safety profiles of different antidiabetes drugs, and support recommendations that favour metformin as first-line therapy for type 2 diabetes.More »

11/28/2009

Many patients with diabetes should forego angioplasties for heart disease and just take medicine instead, according to a new National Institutes of Health study led by Stanford University School of Medicine researcher Mark Hlatky, MD.

Previous research had shown that patients with type-2 diabetes and mild-to-moderate heart disease have no reduction in risk for heart attacks, strokes or death if they have an angioplasty compared with simply taking the right medications. The new study shows that there's substantial cost savings in sticking with drug treatment, with an average savings of $11,000 per patient over four years.More »

09/28/2009

Researchers from Boston University School of Medicine (BUSM) in collaboration with researchers from Lahey Clinic Northshore, Peabody, Mass., believe that androgen deficiency might be the underlying cause for a variety of common clinical conditions, including diabetes, erectile dysfunction, metabolic syndrome and cardiovascular disease (CVD).

These findings appear in the September/October issue of the Journal of Andrology.

Androgens are a steroid hormone, such as testosterone, that controls the development and maintenance of male characteristics. In a number of studies, androgen deficiency has been linked to an increased mortality in men. Testosterone (T) is an anabolic hormone with a wide range of beneficial effects on men's health. However, according to the BUSM researchers, the therapeutic role of T in men's health remains a hotly debated issue for a number of reasons, including the purported risk of prostate cancer.More »

07/30/2009

ScienceDaily — Older patients with diabetes who take antipsychotic medications appear to have an increased risk of hospitalization for hyperglycemia (elevated blood glucose level), especially soon after beginning treatment, according to a report in the July 27 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.More »

07/28/2009

LITTLE FALLS, N.J.- Older patients with diabetes who take antipsychotics may have an increased risk of hyperglycemia, especially soon after treatment, researchers say.

Current use of both typical and atypical antipsychotics was associated with a 1.5-fold increased risk of hospitalization for hyperglycemia, Lorraine L. Lipscombe, MD, of Women's College Hospital in Toronto, and colleagues reported in the July 27 issue of the Archives of Internal Medicine.More »

06/11/2009

June 11: The anti-cholesterol drug fenofibrate appears to reduce risks of amputation for patients with diabetes by as much as 36%, a study has found.

The study was published in a special edition on diabetes by The Lancet.

In the study, researchers in Australia ran a five-year trialMore »

06/11/2009

NEW ORLEANS, June 10 -- Three investigational diet drugs may hold promise for preventing and treating diabetes, researchers said.More »

Syndicate content